本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场
审批编码：PP-BA-CN-4913
获批日期：2024 年 10 月 12 日
内容策划：郭青青
项目审核：曹欢
题图来源：丁香园自制
参考文献
[1] 中国斑秃诊疗指南(2019)[J].临床皮肤科杂志,2020,49(02):69-72.
[2] Alhanshali L, et al. Alopecia Areata Burden of Disease, Approach to Treatment, and Current Unmet Needs. Clin Cosmet Investig Dermatol, 2023, 16:803-820.
[3] Rudnicka L, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687-94.
[4] King B, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023 Nov 16;189(6):666-673.
[5] M. Senna, et al. AAD 2024 Abstract #49690.
[6] Senna M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):583-593.
[7] Mostaghimi A, et al. Among Scalp Non-responder Patients With Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment With Baricitinib Resulted in Meaningful Scalp Responses for Patients With Severe Alopecia Areata. 2024 AAD. Poster 52898.
[8] Wambier CG, et al. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol. 2021 Sep;85(3):743-745.
[9] B. King, et al. AAD 2024 Poster #51436
[10] 巴瑞替尼说明书.
